[Media Releases] Lonza Signs Deal with LegoChem Biosciences to Provide Pre-clinical Material of Therapeutic Compound (IHS Chemical Week, 8 Mar 2012)
Title: Lonza Signs Deal with LegoChem Biosciences to Provide Pre-clinical Material of Therapeutic Compound Publication: IHS Chemical Week Date: 8 Mar 2012 URL: link to website
Lonza says it has signed an agreement with biotech company LegoChem Biosciences (Daejeon, Korea), for the custom material production of a monoclonal antibody that will be used for in vivo proof of concept studies for their technology platform development.
About LegoChem Biosciences LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to discovering, developing, and commercializing innovative medicines by leveraging our chemistry expertise to make conventional biologics targeted and more potent for the benefit of patients with diseases of high unmet medical needs. We are advancing sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC). |